{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:45:36Z","timestamp":1788284736290,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of peribulbar triamcinolone acetonide injection for treating ocular myasthenia gravis (OMG), with a comparison of traditional oral drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 22 patients with OMG who received periocular triamcinolone acetonide injection (initially 20\u00a0mg weekly, then once per month later if symptoms were improved) from July 2019 to July 2022 were evaluated by a comparison of symptom degree before and after treatment. Adverse reactions were also monitored during the period of treatment. The period of follow-up was more than 6 months. Additionally, a comparison of the treatment efficacy between this periocular injection and traditional oral administration was performed in OMG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 4 weeks of treatment, the degree of ptosis in OMG patients decreased to -3.00\u2009\u00b1\u20090.69, compared to the value (-0.86\u2009\u00b1\u20091.32) before treatment. The degree of ophthalmoplegia also decreased from 3.12\u2009\u00b1\u20090.72 to 0.86\u2009\u00b1\u20090.88 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) after treatment. The achievement rates of minimal manifestations status (MMS)for ptosis and ophthalmoplegia after 4 week-treatment were 86.3% and 75%, respectively, while they were 50% and 30% in patients with traditional oral administration. There was statistically significant difference only in MMS (rather than symptom relief rate and generalization conversion rate) between two groups. No serious complications (except for intraorbital hematoma) were found in OMG patients during the treatment period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Repeated peribulbar injection of triamcinolone acetonide can effectively alleviate the initial symptoms of OMG patients. However, the evaluation of its long-term efficacy is still needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registry<\/jats:title>\n                    <jats:p>This study has been clinically registered by Chinese Clinical Trial Registry (ChiCTR), first trial registration date:05\/07\/2019, registration number: ChiCTR1900024285.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-024-03313-z","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T10:02:51Z","timestamp":1705917771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A controlled clinical study on efficacy and safety of periocular triamcinolone acetonide injection for treating ocular myasthenia gravis"],"prefix":"10.1186","volume":"24","author":[{"given":"Minghua","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuneng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijiao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"2","key":"3313_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"key":"3313_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"issue":"12","key":"3313_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00415-010-5651-z","volume":"257","author":"I Casetta","year":"2010","unstructured":"Casetta I, Groppo E, De Gennaro R, Cesnik E, Piccolo L, Volpato S, Granieri E. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010;257(12):2015\u20139.","journal-title":"J Neurol"},{"issue":"4","key":"3313_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"3313_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, et al. International Consensus Guidance for Management of Myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"7","key":"3313_CR6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of Ocular Myasthenia gravis: Retrospective Multicenter Analysis. Ophthalmology. 2015;122(7):1517\u201321.","journal-title":"Ophthalmology"},{"key":"3313_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472\u201399.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"3313_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243\u20138.","journal-title":"Arch Neurol"},{"issue":"6","key":"3313_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB. Factors affecting outcome in myasthenia gravis. Muscle Nerve. 2016;54(6):1041\u20139.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3313_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, McDermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53(3):363\u20139.","journal-title":"Muscle Nerve"},{"issue":"5","key":"3313_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3928\/01913913-20180620-01","volume":"55","author":"YG Lee","year":"2018","unstructured":"Lee YG, Kim US. Efficacy and safety of low-to-moderate dose oral corticosteroid treatment in Ocular Myasthenia Gravis. J Pediatr Ophthalmol Strabismus. 2018;55(5):339\u201342.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"3313_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018;128(1):15\u201324.","journal-title":"Int J Neurosci"},{"key":"3313_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","volume":"209","author":"S Apinyawasisuk","year":"2020","unstructured":"Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S. Factors affecting generalization of Ocular Myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol. 2020;209:10\u20137.","journal-title":"Am J Ophthalmol"},{"key":"3313_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1196\/annals.1405.037","volume":"1132","author":"J Soltys","year":"2008","unstructured":"Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci. 2008;1132:220\u20134.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"3313_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00234-021-02753-4","volume":"63","author":"G Velonakis","year":"2021","unstructured":"Velonakis G, Papadopoulos VE, Karavasilis E, Filippiadis DK, Zouvelou V. MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis. Neuroradiology. 2021;63(9):1531\u20138.","journal-title":"Neuroradiology"},{"issue":"21","key":"3313_CR16","doi-asserted-by":"publisher","first-page":"12062","DOI":"10.1073\/pnas.211257298","volume":"98","author":"JD Porter","year":"2001","unstructured":"Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Andrade FH. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA. 2001;98(21):12062\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3313_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1196\/annals.1254.043","volume":"998","author":"HJ Kaminski","year":"2003","unstructured":"Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci. 2003;998:362\u201374.","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"3313_CR18","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","volume":"88","author":"R Ebner","year":"2004","unstructured":"Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, Bonelli L, Niepomniszcze H. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88(11):1380\u20136.","journal-title":"Br J Ophthalmol"},{"key":"3313_CR19","doi-asserted-by":"crossref","first-page":"204201882095833","DOI":"10.1177\/2042018820958335","volume":"11","author":"J L\u00e4ngericht","year":"2020","unstructured":"L\u00e4ngericht J, Kr\u00e4mer I, Kahaly GJ. Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application. Therapeutic Adv Endocrinol Metabolism. 2020;11:2042018820958335.","journal-title":"Therapeutic Adv Endocrinol Metabolism"},{"issue":"1","key":"3313_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1755-3768.2008.01171.x","volume":"87","author":"M Bordaberry","year":"2009","unstructured":"Bordaberry M, Marques DL, Pereira-Lima JC, Marcon IM, Schmid H. Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves\u2019 ophthalmopathy. Acta Ophthalmol. 2009;87(1):58\u201364.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"3313_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12886-020-01697-2","volume":"20","author":"M Shi","year":"2020","unstructured":"Shi M, Ye Y, Zhou J, Qin A, Cheng J, Ren H. Local use of dexamethasone in the treatment of ocular myasthenia gravis. BMC Ophthalmol. 2020;20(1):432.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"3313_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"key":"3313_CR23","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2147\/OPTH.S261259","volume":"14","author":"T Threetong","year":"2020","unstructured":"Threetong T, Poonyathalang A, Preechawat P, Jindahra P, Padungkiatsagul T, Vanikieti K. Initial treatment response in Ocular Myasthenia gravis: a comparison between low and moderate doses of Prednisolone. Clin Ophthalmol (Auckland NZ). 2020;14:2051\u20136.","journal-title":"Clin Ophthalmol (Auckland NZ)"},{"issue":"6","key":"3313_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","volume":"29","author":"E Fortin","year":"2018","unstructured":"Fortin E, Cestari DM, Weinberg DH. Ocular myasthenia gravis: an update on diagnosis and treatment. Curr Opin Ophthalmol. 2018;29(6):477\u201384.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"3313_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08164622.2022.2029683","volume":"105","author":"NH Shuey","year":"2022","unstructured":"Shuey NH. Ocular myasthenia gravis: a review and practical guide for clinicians. Clin Experimental Optometry. 2022;105(2):205\u201313.","journal-title":"Clin Experimental Optometry"},{"issue":"10","key":"3313_CR26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89(10):1330\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3313_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","volume":"77","author":"A Evoli","year":"1988","unstructured":"Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988;77(1):31\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"3313_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","volume":"53","author":"MJ Kupersmith","year":"1996","unstructured":"Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol. 1996;53(8):802\u20134.","journal-title":"Arch Neurol"},{"issue":"6","key":"3313_CR29","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology"},{"key":"3313_CR30","doi-asserted-by":"publisher","first-page":"117274","DOI":"10.1016\/j.jns.2020.117274","volume":"420","author":"R Verma","year":"2021","unstructured":"Verma R, Wolfe GI, Kupersmith MJ. Ocular myasthenia gravis - how effective is low dose prednisone long term? J Neurol Sci. 2021;420:117274.","journal-title":"J Neurol Sci"},{"key":"3313_CR31","doi-asserted-by":"crossref","unstructured":"Kemchoknatee P, Armornpetchsathaporn A, Tangon D, Srisombut T. Age of onset and factors affecting treatment responses in ocular myasthenia gravis. Int Ophthalmol 2023.","DOI":"10.1007\/s10792-023-02676-4"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03313-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03313-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03313-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T10:05:46Z","timestamp":1705917946000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03313-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3313"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03313-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2910211\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of Aier Eye Hospital of Wuhan University, China (approval no.: HYEYE2019IRB05). Written informed consent was obtained from each patient or their parents (for children\u2009<\u200918 years of age) prior to participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained explicit written informed consent to publish all data (including individual details, images or videos) related to the study from patients or\u2002their\u2002parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}